Lexicon completes enrollment in Phase 3 SONATA-HCM trial of sotagliflozin in symptomatic hypertrophic cardiomyopathy

• Lexicon Pharmaceuticals completed patient randomization in the Phase 3 SONATA-HCM trial of sotagliflozin in symptomatic hypertrophic cardiomyopathy.
• The study exceeded its 500-patient enrollment target across more than 130 sites in 20 countries, supporting a broad readout across obstructive and non-obstructive disease.
• Topline results have not been presented; the first results are expected in Q1 2027.
• The trial is designed to show whether sotagliflozin improves patient symptoms and daily function versus placebo, with safety assessed in parallel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270830PRIMZONEFULLFEED9767995) on July 27, 2026, and is solely responsible for the information contained therein.